Report of the workgroup on viral diseases

Bulletin of the World Health Organization

Volumn 76, Issue SUPPL. 2, 1998, Pages 94-102

  Losos, J ^a  

^a HEALTH CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HEALTH; HEALTH CARE PLANNING; HUMAN; INTERNATIONAL COOPERATION; ORGANIZATION; VIRUS INFECTION;

HEALTH PLANNING; HUMANS; INTERNATIONAL COOPERATION; ORGANIZATIONAL OBJECTIVES; VIRUS DISEASES; WORLD HEALTH;

EID: 0032241369     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hadler SC. Global impact of hepatitis A virus infection changing patterns. In: Hollinger FB et al. eds. Viral hepatitis and liver disease. Baltimore, MD, Williams & Wilkins, 1991: 14-20.
2. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices. Morbidity and mortality weekly report, 1996, 45 (RR-15): 1-30.
3. Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis A virus infection. Journal of hepatology, 1994, 18(suppl. 2): s11-14.
4. Lemon SM. Type A viral hepatitis: new developments in an old disease. New England journal of medicine, 1985, 313: 1059-1067.
5. Innis B L et al. Protection against hepatitis A by an inactivated vaccine. Journal of the American Medical Association, 1994, 271: 1328-1334.
6. Werzberger A et al. A controlled trial of formalin-inactivated hepatitis A vaccine in healthy children. New England journal of medicine, 1992, 327: 453-457.
7. Maynard JE, Kane MA, Hadler SC. Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization. Reviews of infectious diseases, 1989, 11: s574-578.
8. Olivé JM, Aylward BR, Melgaard B. Disease eradication as a public health strategy: is measles next? World health statistic quarterly, 1997, 50: 185-187.
9. Murray CJL, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 projected to 2020 - summary. Geneva, World Health Organization, 1996: 17-26.
10. Cults FT. The immunological basis for immunization: measles. Unpublished document WHO/EPI/GEN/93.17, 1993 (available upon request from Global Programme for Vaccines and Immunization, World Health Organization, 1211 Geneva 27, Switzerland).
11. Expanded Programme on Immunization. EPI Information System: global summary, August 1997. Unpublished document WHO/EPI/GEN 97.02 (available upon request from Global Programme for Vaccines and Immunization, World Health Organization, 1211 Geneva 27, Switzerland).
12. Cults FT et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries. 1: Burden of disease from CRS. Bulletin of the World Health Organization, 1997, 75: 55-68.
13. Robertson SE et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries. 2: Vaccination against rubella. Bulletin of the World Health Organization, 1997, 75: 69-80.
14. Monath TP. Yellow fever: Victor, victoria? Conqueror, conquest? Epidemics and research in the last 40 years and prospects for the future. American journal of tropical medicine and hygiene, 1991, 45: 1-43.
15. Monath TP. Yellow fever vaccine. In: Plotkin SA, Mortimer EA. eds. Vaccines, 3rd ed. Philadelphia, WB Saunders, (in press).
16. Monath TP. Epidemiology of yellow fever: current status and speculations on future trends. In: Saluzzo JF, Dodets G. eds. Factors in the emergence of arbovirus diseases. Paris, Elsevier, 1997: 143-156.
17. Pan American Health Organization. Present status of yellow fever: Memorandum from a PAHO meeting. Bulletin of the World Health Organization, 1986, 64: 511-524.
18. Gratz NA, Knudsen AB. The rise and spread of dengue, dengue haemorrhagic fever and its vectors - a historical review. Unpublished document CTD/FIL (DEN) 96.7, 1996.
19. Roberlson SE et al. Yellow fever: a decade of reemergence. Journal of the American Medical Association, 1996, 276: 1157-1162.
20. Prevention and control of yellow fever in Africa. Geneva, World Health Organization, 1986.
21. Monath TP, Nasidi A. Should yellow fever vaccine be included in the Expanded Programme of Immunization in Africa? A cost-effectiveness analysis. American journal of tropical medicine and hygiene, 1993, 48: 274-299.
22. Centers for Disease Control and Prevention. Compendium of animal rabies control, 1997. National Association of State Public Health Veterinarians, Inc. Morbidity and mortality weekly report, 1997, 46: 1-9.
23. Centers for Disease Control and Prevention. Rabies prevention - United States, 1991: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbidity and mortality weekly report, 1991, 40 (RR-3): 1-19.
24. WHO Expert Committee on Rabies. Eighth Report. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 824).
25. World survey of rabies No. 30 for the year 1994. Unpublished WHO document WHO/EMC/ZOO/96.3, 1996.
26. Baer GM. Oral rabies vaccination: an overview. Reviews of infectious diseases, 1988, 10 (Suppl. 4): S644-S648.
27. Smith JS, Orciari LA, Yager PA. Molecular epidemiology of rabies in the United States. Seminars in virology, 1995, 6: 387-400.
28. Meslin F-X, Fishbein DB, Matter HC. Rationale and prospects for rabies elimination in developing countries. In: Rupprecht CE et al. eds. Current topics in microbiology and immunology, Berlin, Springer-Verlag, 1994: 1-26.
29. Rupprecht CE et al. The ascension of wildlife rabies: a cause for public health concern or intervention? Emerging infectious diseases, 1995, 1: 107-114.
30. Hanlon CA, Rupprecht CE. The reemergence of rabies. In: Scheld WM et al. eds. Emerging infections, Washington, DC, ASM Press: 1998: 59-80.
31. Allworth A, Murray K, Morgan J. A human case of encephalitis due to a lyssavirus recently identified in fruit bats. Communicable diseases intelligence, 1996, 20: 504.
32. Burke DS, Leake CJ. Japanese encephalitis. In: Monath TP. ed. The arboviruses: epidemiology and ecology, Vol. III. Boca Raton, CRC Press, 1988: 63-92.
33. Tsai TF, Chang GJ, Yu YX. Japanese encephalitis vaccines. In: Plotkin S, Orenstein W. Vaccines, 3rd ed. Philadelphia, WB Saunders, (in press).
34. Rojanosuphot S, Tsai TF. eds. Regional workshop on control strategies for Japanese encephalitis. Southeast Asia journal of tropical medicine and public Health, 1995, 26 (S3): 1-59.
35. Mackenzie JS et al. Emergence of Japanese encephalitis virus in the Australasian region. In: Salluzzo JF, Dodet B. eds. Factors in the emergence of arbovirus diseases. Paris, Elsevier, 1997: 191-201.
36. Vaughn DW, Hoke CH. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiological reviews, 1992, 14: 197-221.
37. Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immuni-zation Practices (ACIP). Morbidity and mortality weekly report, 1993, 42 (RR-1).
38. Plesner AM, Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine, 1997, 15: 1239-1243.
39. Hennessy S et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet, 1996, 347: 1583-1586.